The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and chemotherapy alone.

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...

What Is HER2-Positive Breast Cancer? HER2-positive breast cancer is when breast cancer cells have a protein receptor called human epidermal growth factor receptor 2 (HER2). Normally, this protein ...

The potential to treat GEA by targeting HER2 was confirmed in 2010 when researchers showed that adding Roche’s Herceptin to chemotherapy extended OS from 11.1 months to 13.8 months. There were ...

BARCELONA, Spain — Trastuzumab deruxtecan (TDXd) shows promise as a treatment for HER2-low and HER2-ultralow hormone receptor (HR)–positive metastatic breast cancer, according to data from the ...

A study demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive advanced or metastatic breast cancer, including those with brain metastases. Senior author ...

Evaluate the efficacy and safety profiles of current and emerging HER2-directed therapies in NSCLC, and their potential impact on treatment paradigms. (Bazhenova) Describe the difference between ...

The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic HER2-low or -ultralow breast cancer. The Food and Drug Administration (FDA) ...

"As many as half of patients with HER2-positive breast cancer develop brain metastases, which often has a poorer prognosis than breast cancer that hasn't spread to the brain," says Nancy Lin ...

Designer Jonathan Simkhai strikes a pose with "Fight Night" star Taraji P. Henson. Supermodel Amber Valletta (inset) opened his spring show. Bahram Hakkakian/InDigital Taraji P. Henson coordinates ...